Comparing myocardial injury patterns and outcomes in cardiac magnetic resonance imaging between COVID-19- and non-COVID-19-related myocarditis.

Shokoufeh Hajsadeghi, Mohammad Kasaei, Hamidreza Pouraliakbar, Sepehr Jamalkhani, Shayan Mirshafiee
Author Information
  1. Shokoufeh Hajsadeghi: Research Centre for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
  2. Mohammad Kasaei: Department of Imaging, Shiraz University of Medical Sciences, Shiraz, Iran.
  3. Hamidreza Pouraliakbar: Department of Radiology, Rajaie Cardiovascular and Medical Research Centre, Iran University of Medical Sciences, Tehran, Iran.
  4. Sepehr Jamalkhani: Department of Cardiology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  5. Shayan Mirshafiee: Department of Cardiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Purpose: Despite the low incidence of COVID myocarditis, its influence on outcomes is substantial. The pivotal role of cardiac magnetic resonance (CMR) in diagnosing myocarditis is considered to be associated with disease prognosis. The primary objective of this study was to conduct a comparative analysis of myocardial injury patterns, CMR pathologic features, outcomes, and their correlation with CMR findings in COVID- and non-COVID-related myocarditis.
Material and methods: This historical cohort study involved 124 patients diagnosed with myocarditis (COVID-19 or non-COVID-19), who underwent CMR between 2018 and 2021. The COVID group consisted of 70 individuals with a definite history of COVID-19 infection within 4 weeks, and the non-COVID group comprised 54 individuals who had no prior exposure to the SARS-CoV-2 virus. All patients were monitored for one year to assess the incidence of major adverse cardiovascular events (MACE). Additionally, baseline and follow-up echocardiography data were obtained with a minimum 3-month interval.
Results: In comparison between two groups regarding to indices of CMR, left ventricular (LV) ejection fraction ( < 0.001), right ventricular (RV) ejection fraction ( < 0.001) were significantly lower in non-COVID group, and significant LV and RV systolic dysfunction were meaningfully lower in the COVID group. Extension of late gadolinium enhancement (LGE) was significantly greater in COVID group. Finally, the incidence of MACE and mean event-free survival did not have significant difference between two groups.
Conclusions: Although CMR findings differed between the 2 groups, there was no significant difference in the risk of MACE or survival during one-year follow-up. Notably, LV and RV dysfunction were more prevalent in the non-COVID group, while extension of LGE was greater in the COVID group.

Keywords

References

  1. JAMA Cardiol. 2020 Jul 1;5(7):811-818 [PMID: 32219356]
  2. J Am Heart Assoc. 2022 Jan 4;11(1):e022010 [PMID: 34970914]
  3. Radiol Cardiothorac Imaging. 2019 Jul 25;1(3):e190010 [PMID: 33778510]
  4. J Magn Reson Imaging. 2014 Dec;40(6):1347-54 [PMID: 24293405]
  5. Eur J Pediatr. 2022 Jul;181(7):2879-2883 [PMID: 35482094]
  6. Circulation. 2022 Apr 12;145(15):1123-1139 [PMID: 35404682]
  7. Clin Cardiol. 2022 Jan;45(1):110-118 [PMID: 35005792]
  8. JAMA. 2020 Aug 11;324(6):603-605 [PMID: 32644129]
  9. Lancet Infect Dis. 2020 May;20(5):533-534 [PMID: 32087114]
  10. Circ Heart Fail. 2020 Nov;13(11):e007405 [PMID: 33176455]
  11. Circulation. 2002 Jan 29;105(4):539-42 [PMID: 11815441]
  12. Eur Heart J. 2021 May 14;42(19):1866-1878 [PMID: 33596594]
  13. Lancet. 2021 Aug 28;398(10302):747-758 [PMID: 34454673]
  14. Circulation. 2007 Nov 6;116(19):2216-33 [PMID: 17959655]
  15. Infect Disord Drug Targets. 2023;23(1):e100622205846 [PMID: 35692134]
  16. J Am Coll Cardiol. 2020 Aug 4;76(5):533-546 [PMID: 32517963]
  17. JAMA Cardiol. 2021 Jan 1;6(1):116-118 [PMID: 32915194]
  18. Viruses. 2022 Dec 14;14(12): [PMID: 36560794]
  19. Kardiol Pol. 2023;81(5):463-471 [PMID: 36871296]
  20. JAMA Cardiol. 2020 Nov 01;5(11):1265-1273 [PMID: 32730619]
  21. J Am Coll Cardiol. 2017 Oct 17;70(16):1964-1976 [PMID: 29025553]
  22. Lancet. 2023 Jun 17;401(10393):e21-e33 [PMID: 37321233]
  23. J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176 [PMID: 30545455]
  24. Clin Microbiol Infect. 2021 Feb;27(2):258-263 [PMID: 33031948]
  25. Eur Heart J. 2022 Mar 14;43(11):1157-1172 [PMID: 35176758]
  26. Clin Chem. 2021 Aug 5;67(8):1080-1089 [PMID: 33860295]
  27. JAMA Cardiol. 2020 Jul 1;5(7):802-810 [PMID: 32211816]
  28. Eur Heart J. 2007 Jun;28(11):1326-33 [PMID: 17493945]
  29. Cardiovasc Pathol. 2021 Sep-Oct;54:107362 [PMID: 34192559]
  30. Nat Med. 2021 Apr;27(4):601-615 [PMID: 33753937]
  31. Radiology. 2022 Sep;304(3):E48-E49 [PMID: 35503017]
  32. Circ Cardiovasc Imaging. 2021 Jan;14(1):e011492 [PMID: 33441003]
  33. JACC Cardiovasc Imaging. 2022 Apr;15(4):705-707 [PMID: 34922867]

Word Cloud

Created with Highcharts 10.0.0groupCOVIDmyocarditisCMRincidenceoutcomescardiacmagneticresonancenon-COVIDMACEgroupsLVRVsignificantstudymyocardialinjurypatternsfindingspatientsCOVID-19individualsfollow-uptwoventricularejectionfraction<0001significantlylowerdysfunctionLGEgreatersurvivaldifferenceimagingPurpose:DespitelowinfluencesubstantialpivotalrolediagnosingconsideredassociateddiseaseprognosisprimaryobjectiveconductcomparativeanalysispathologicfeaturescorrelationCOVID-non-COVID-relatedMaterialmethods:historicalcohortinvolved124diagnosednon-COVID-19underwent20182021consisted70definitehistoryinfectionwithin4weekscomprised54priorexposureSARS-CoV-2virusmonitoredoneyearassessmajoradversecardiovasculareventsAdditionallybaselineechocardiographydataobtainedminimum3-monthintervalResults:comparisonregardingindicesleftrightsystolicmeaningfullyExtensionlategadoliniumenhancementFinallymeanevent-freeConclusions:Althoughdiffered2riskone-yearNotablyprevalentextensionComparingCOVID-19-non-COVID-19-related

Similar Articles

Cited By

No available data.